Venkatachalam Mangeshkumar, MD
Neurology · Lititz, PANPI 1730173485
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $81,196 of the $135,140 with a category attached, or 60.1%. 60 manufacturers reported payments, led by EMD Serono, Inc. at 39.0% of the total. Reporting peaked in 2019 at $57,969 and has fallen 99.3% since, to $425 in 2024. Among neurology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,101 payments — averaging $122.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$53K
- AstraZeneca$50K
- Genentech USA, Inc.$10K
- Mallinckrodt Hospital Products Inc.$3K
- AbbVie$2K
- Catalyst Pharmaceuticals, Inc.$2K
- plus $16K from 54 others
Across 30 payments — averaging $409.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- MDD US Operations, LLC$9K
- Mallinckrodt Hospital Products Inc.$2K
- Mallinckrodt Enterprises LLC$1K
What the payments were for
- Consulting fees$13,95510%
- Speaking & faculty fees$81,19660%
- Travel & lodging$14,88511%
- Food & beverage$25,05919%
- Education$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$135,140 in reported general payments places this provider in the 90th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SolirisEculizumab | 13 | $633,649 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 14 | $407,716 |
| AustedoDeutetrabenazine | 28 | $216,772 |
| CopaxoneGlatiramer Acetate | 20 | $112,950 |
| FycompaPerampanel | 28 | $29,912 |
| Emgality PenGalcanezumab-Gnlm | 22 | $15,080 |
| QuliptaAtogepant | 14 | $15,026 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 12 | $9,776 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $9,223 |
| Rasagiline Mesylate | 37 | $5,573 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 151 | $4,501 |
| Gabapentin | 211 | $3,871 |
| Pyridostigmine Bromide | 13 | $3,746 |
| Primidone | 109 | $3,391 |
| Levetiracetam | 129 | $3,323 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSoliris | $49,840 | $633,64913 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Copaxone | $1,026 | $329,72248 claims |
| Eisai Inc.Fycompa | $683 | $29,91228 claims |
| AbbVieQulipta | $2,379 | $15,02614 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $196 | $3,74613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 941 neurology providers in Pennsylvania.
Other neurology in Lititz
- Daniel KremensPhiladelphia$1.8M
- Thomas LeistPhiladelphia$1.4M
- Jill Giordano FarmerPhiladelphia$1.2M
- Ravi DukkipatiYork$936K
- Brad KleinAbington$927K
- Stephanie Nahas-GeigerPhiladelphia$786K
- John KhouryAbington$686K
- Amit Bar-OrPhiladelphia$596K
- Behrang SaminejadAllentown$594K
- Anoopum GuptaPittsburgh$592K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.